ComGenex Announces Extension of the Medicinal Chemistry Synthesis Space
News Jan 18, 2006
ComGenex, Inc. has disclosed that it has tested and completed the initial phase of the integration of the first ever continuous flow, bench top ozonolyzis unit into its high-throughput organic synthesis technology line.
The O-Cube is member of the Cube-series developed by Thales Nanotechnology Inc., a former spin-out of ComGenex.
This device is designed to utilise proprietary technologies, including microfluidics and internal ozone generation in order to safely carry out a wide variety of organic transformations under pressure and even at room temperature.
The shoe-box sized unit is fully portable and easy to use in small scale with individual compounds.
According to Dr. Ferenc Darvas, President and Chairman of Thales Nanotechnology, "We believe that the introduction of safe ozonolyzis into routine laboratory practice will significantly enlarge the toolkit of present-day medicinal chemists."
"The application of ozonolyzis, an important chemical transformation, has so far been seriously limited due to the high explosion risk and the low reaction temperature (typically -30 to -40 Celsius). Upon the positive laboratory results achieved at ComGenex, we strive to speed up the commercial launch of O-Cube."
Dr. Laszlo Urge, CEO of ComGenex, Inc. commented, "ComGenex has tested this unit extensively and used it in the production of exclusive compound libraries."
"According to our experience, the device can create compounds that can not be synthesised by conventional batch technologies."
"Therefore, it will open new avenues in the field of medicinal chemistry and it will also contribute to the increase of the chemical diversity in compound libraries. It also provides great support to our ongoing medicinal chemistry projects."
"Once it is commercially available, we expect that, as with its predecessor the H-Cube, it will revolutionise the way ozonolyzis is carried out in medicinal chemistry labs in the future."
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE